Geographic Variations and the associated Factors in adherence to and Persistence With adjuvant Hormonal therapy For the Privately insured Women aged 18-64 With Breast Cancer in Texas

Authors

Junghyun Kim
Man S Kim
Suja S Rajan
Xianglin L Du
Luisa Franzini
Tae Gi Kim
Sharon H Giordano
Robert O Morgan

Publication Date

3-29-2023

Journal

Current Oncology

Abstract

The purpose of this study is to examine the geographical patterns of adjuvant hormonal therapy adherence and persistence and the associated factors in insured Texan women aged 18-64 with early breast cancer. A retrospective cohort study was conducted using 5-year claims data for the population insured by the Blue Cross Blue Shield of Texas (BCBSTX). Women diagnosed with early breast cancer who were taking tamoxifen or aromatase inhibitors (AIs) for adjuvant hormonal therapy with at least one prescription claim were identified. Adherence to adjuvant hormonal therapy and persistence with adjuvant hormonal therapy were calculated as outcome measures. Women without a gap between two consecutively dispensed prescriptions of at least 90 days were considered to be persistently taking the medications. Patient-level multivariate logistic regression models with repeated regional-level adjustments and a Cox proportional hazards model with mixed effects were used to determine the geographical variations and patient-, provider-, and area-level factors that were associated with adjuvant hormonal therapy adherence and persistence. Of the 938 women in the cohort, 627 (66.8%) initiated adjuvant hormonal therapy. Most of the smaller HRRs have significantly higher or lower rates of treatment adherence and persistence rates relative to the median regions. The use of AHT varies substantially from one geographical area to another, especially for adherence, with an approximately two-fold difference between the lowest and highest areas, and area-level factors were found to be significantly associated with the compliance of AHT. There are geographical variations in AHT adherence and persistence in Texas. Patient-level and area-level factors have significant associations explaining these patterns.

Keywords

Female, Humans, Breast Neoplasms, Texas, Retrospective Studies, Antineoplastic Agents, Hormonal, Chemotherapy, Adjuvant, Medication Adherence, Insurance, Health